| 42.53 Delayed Data As of Oct 18 |  +0.06 / +0.14%Today’s Change | 36.41 Today|||52-Week Range 43.22 | +11.31% Year-to-Date |
| Better Buy: GlaxoSmithKline vs. Merck Oct 15 / MotleyFool.com - Paid Partner Content | Will The Pace of M&A Pick Up Following The Biotech Sector’s Pounding? Oct 11 / MotleyFool.com - Paid Partner Content |
| Previous close | 42.47 |
| Today’s open | 42.52 |
| Day’s range | 42.37 - 42.64 |
| Volume | 1,428,142 |
| Average volume (3 months) | 2,283,498 |
| Market cap | $106.1B |
| Earnings growth (last year) | +143.10% |
| Earnings growth (this year) | -6.95% |
| Earnings growth (next 5 years) | +3.50% |
| Revenue growth (last year) | +5.72% |
| P/E ratio | 18.4 |
| Price/Sales | 2.31 |
| Price/Book | 18.85 |
| Today’s change | Today’s % change | |
|---|---|---|
| LLYEli Lilly and Co | +0.18 | +0.17% |
| ABBVAbbVie | +1.32 | +1.76% |
| AZNAstraZeneca | -0.26 | -0.59% |
| SNYSanofi | -0.33 | -0.71% |
| Next reporting date | October 30, 2019 |
| EPS forecast (this quarter) | $0.80 |
| Annual revenue (last year) | $41.1B |
| Annual profit (last year) | $4.8B |
| Net profit margin | 11.75% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Brentford, Greater London |
